Everything below concerns Metabolic modulator. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
=== Ports === Half-Life 2 was released on the Xbox console by Electronic Arts in November 2005. In 2006, Valve partnered with Taito to release Half-Life 2: Survivor, an arcade game, for the Japanese market. Valve re-released Half-Life 2 as part of the 2007 compilation The Orange Box for Windows, Xbox 360 and PlayStation 3. On May 26, 2010, Half-Life 2, Episode One and Episode Two were released for Mac OS X. In 2013, Valve ported Half-Life 2 to Linux and released a free update adding support for the Oculus Rift virtual reality headset. An Nvidia Shield Tablet-exclusive port for Android was released on May 12, 2014.
The CHON principle was born to meet this further process requirement, according to which all extractants and molecular reagents used in the developed processes have only to contain atoms of carbon (C), hydrogen (H), oxygen (O) and nitrogen (N), thus incinerable waste to easily release into the environment.
== Mutations == Mutations in genes encoding uniporters lead to dysfunctional transporter proteins being formed. This loss of function in uniporters causes disruption in cellular function which leads to various diseases and disorders.
== Plot == Following a news story depicting the demolition of a slum in East London in the south-east of the Cape Province in South Africa, liberal white South African journalist Donald Woods seeks more information about the incident and ventures off to meet the anti-Apartheid black activist Steve Biko, a leading member of the Black Consciousness Movement. Biko has been officially banned by the National Party-led government and is not permitted to leave his defined 'banning area' at King William's Town. Woods is opposed to Biko's banning, but remains critical of his political views. Biko invites Woods to visit a black township to see the impoverished conditions and to witness the effect of the Government-imposed restrictions, which make up the apartheid system. Woods begins to agree with Biko's desire for a South Africa where blacks have the same opportunities and freedoms as those enjoyed by the white population. As Woods comes to understand Biko's point of view, a friendship slowly develops between them. After speaking at a gathering of black South Africans outside of his banishment zone, Biko is arrested and interrogated by the South African security forces (who have been tipped off by an informer). Following this, he is brought to court in order to explain his message directed toward the South African Government, which is white minority-controlled. After he speaks eloquently in court and advocates non-violence, the security officers who interrogated him visit his church and vandalise the property.
== Adverse effects == Side effects of ramelteon include somnolence (3% vs. 2% for placebo), fatigue (3% vs. 2% for placebo), dizziness (4% vs. 3% for placebo), nausea (3% vs. 2% for placebo), and exacerbated insomnia (3% vs. 2% for placebo). Overall, side effects occurred in 6% with ramelteon and 2% with placebo in clinical trials. Side effects leading to discontinuation occurred in 1% or fewer people. Rarely, anaphylactic reactions, abnormal thinking, and worsening of depression or suicidal thinking in patients with pre-existing depression may occur with ramelteon. Ramelteon has been found to slightly increase prolactin levels in women (+34% vs. –4% with placebo) but not in men and to decrease free testosterone levels (by 3–6% in younger men and by 13–18% in older men). Ramelteon has not been shown to produce dependence and has shown no potential for abuse. The withdrawal and rebound insomnia that is typical with GABAA receptor positive modulators like benzodiazepines and Z-drugs is not present in ramelteon. Increased incidence of liver and testicular tumors have been observed with ramelteon in rodents but only at doses equivalent to at least 20 times greater than the recommended dose in humans.
Sources: en.wikipedia.org
=== Bed bugs === Two mutations, the valine to leucine mutation (V419L) and the leucine to isoleucine mutation (L925I) in voltage-gated sodium channel α-subunit gene, have been identified as responsible for knockdown resistance to deltamethrin in bed bugs. One study found that 88% of bed bug populations in the US had at least one of the two mutations, if not both, meaning that deltamethrin resistance among bed bugs is currently making this insecticide obsolete.
After 1900, once the dual nature of lichens was accepted, researchers set out to place them in a coherent taxonomic framework. For the next half-century, lichenologists treated lichens as a distinct fungal subclass—separate from other fungi yet organized by fungal traits. Alexander Zahlbruckner's monumental work epitomized this approach. Between 1907 and 1922, Zahlbruckner issued the multi-volume Catalogus Lichenum Universalis, a comprehensive catalogue and classification of every lichen then known. He first separated lichens by fungal class: the common Ascolichenes, with ascomycete hosts, and the rarer Basidiolichenes, built on basidiomycete hosts. Within Ascolichenes he next used fruiting-body form: taxa with exposed disc-like apothecia formed the Gymnocarpeae (roughly today's Lecanoromycetes), whereas those with flask-shaped, enclosed fruiting bodies became the Pyrenocarpeae (comparable to modern Ostropomycetidae). He further split these into families and suborders on spore and apothecial details—for example, Graphidineae for crustose taxa with carbonised, branching fruiting bodies (e.g., Graphis) and Cyclocarpineae for lichens bearing shield-shaped apothecia across several thallus types. Although the scheme still sat outside the broader fungal code, prioritising traits thought to track fungal evolution brought it closer to a natural system. Zahlbruckner's catalogue soon became the global standard, prized for its exhaustive synthesis even though several groupings later proved artificial. Early-20th-century schemes put the fungal partner's morphology and chemistry first.
The AAV genome is built of single-stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises ITRs at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact to form a capsid with icosahedral symmetry.
== See also == Isotope geochemistry List of elements by stability of isotopes List of nuclides (991 nuclides in order of stability, all with half-lives over one hour) Mononuclidic element Periodic table Primordial nuclide Radionuclide Stable isotope ratio Table of nuclides Valley of stability
=== A10AE Insulins and analogues for injection, long-acting === A10AE01 Insulin (human) A10AE02 Insulin (beef) A10AE03 Insulin (pork) A10AE04 Insulin glargine A10AE05 Insulin detemir A10AE06 Insulin degludec A10AE07 Insulin icodec A10AE30 Combinations A10AE54 Insulin glargine and lixisenatide A10AE56 Insulin degludec and liraglutide A10AE57 Insulin icodec and semaglutide
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.